F
Fred M. Gordin
Researcher at Veterans Health Administration
Publications - 102
Citations - 25516
Fred M. Gordin is an academic researcher from Veterans Health Administration. The author has contributed to research in topics: Tuberculosis & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 45, co-authored 100 publications receiving 24396 citations. Previous affiliations of Fred M. Gordin include San Francisco General Hospital & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial.
Nila J. Dharan,Jacqueline Neuhaus,Juergen K. Rockstroh,Lars Peters,Fred M. Gordin,Alejandro Arenas-Pinto,Carol Emerson,Kristen M. Marks,Jose Hidalgo,Rui Sarmento-Castro,Christoph Stephan,Nagalingeswaran Kumarasamy,Sean Emery,Sean Emery,Gail V. Matthews +14 more
TL;DR: Significant liver fibrosis was rare among ART‐naïve HIV‐positive persons with high CD4 counts and a benefit of early ART in preventing the development of liver Fibrosis is suggested.
Journal ArticleDOI
Rates of tuberculosis infection in healthcare workers providing services to HIV-infected populations
Karen Zahnow,John P. Matts,David Hillman,Elizabeth Finley,Lawrence S. Brown,Ramon A. Torres,Jerome Ernst,Wafaa El-Sadr,George Perez,C. A. Webster,Beverly Barber,Fred M. Gordin +11 more
TL;DR: These data provide some reassurance that caring for HIV-infected patients is not related to an increased rate of TB infection among HCWs in these settings, as well as determining prospectively the incidence of new infections in this population.
Journal ArticleDOI
Tuberculosis control. Back to the future
TL;DR: The fear of widespread dissemination of TB to other patients, health care workers, and the general public has prompted interest in reopening special TB facilities, but would these facilities, in fact, be reopened?
Journal ArticleDOI
Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment: Report of a Veterans Affairs Cooperative Study
Michael S. Simberkoff,Pamela M. Hartigan,John D. Hamilton,Philip L. Day,Gigi R. Diamond,G. Dickinson,George L. Drusano,Merrill J. Egorin,W. Lance George,Fred M. Gordin,Clifton A. Hawkes,Peter Jensen,Nancy G. Klimas,Ann M. Labriola,Christopher J. Lahart,William A. O'Brien,Charles N. Oster,Kent J. Weinhold,Nelda P. Wray,Susan B. Zolla Pazner +19 more
TL;DR: It is concluded that early zidovudine therapy delays progression to AIDS but does not affect survival, and patients who progress to AIDS while on prolonged zidvudine monotherapy many benefit from a change to other antiretroviral therapy(ies).
Journal ArticleDOI
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: The STALWART study
Jorge A. Tavel,Abdel Babiker,Cate Carey,Martin Fisher,Lawrence Fox,Daniela Gey,Gustavo Lopardo,Juan Carlos López,Norman Markowitz,David Munroe,Nicholas I. Paton,Kiat Ruxrungtham,Barbara Standridge,Deborah Wentworth,Nicole Wyman,Bitten Aagaard,Liselotte Borup,Jesper Grarup,Per O. Jansson,Karoline Jensen,Jens D Lundgren,David Mollerup,Søren Reilev,Nafisah Braimah,Janet Darbyshire,Jessica Horton,Eleanor King,Nicki Smith,Fionna Van Hooff,David A. Cooper,David Courtney-Rodgers,Sean Emery,Elizabeth Finley,Fred M. Gordin,Adriana Sanchez,Doug Thomas,Judith Bebchuk,Patty Bollenbeck,Eileen Denning,Alain G. DuChene,Lisa Fosdick,Merrie Harrison,Eric A. Krum,Gregg Larson,James D. Neaton,Ray Nelson,Kien Quan,Siu Fun L. Quan,Terri Schultz,Greg Thompson,Simon Collins,David Haerry,Michael Meulbroek,Dwight E. Peavy,Claire Rappoport,Siegfried Schwarze,Mirta Valdez,Jo Watson,Waldo H. Belloso,Rick Davey,Daniel Duprez,José M. Gatell,Jenny Hoy,Alan R. Lifson,Court Pederson,George Perez,Richard J. Price,Ronald J. Prineas,Frank S. Rhame,James H. Sampson,John Worley,John F. Modlin,Valerie Beral,Richard E. Chaisson,Thomas R. Fleming,Christopher Hill,Kyung Mann Kim,Barbara E. Murray,Billy Pick,Maxime Seligmann,Ian Weller,Mary Anne Luzar,Ana Martinez,Vanita Costas,Julie Eckstrand,Shawn K. Brown,Sergio H. Lupo,Marcelo H. Losso,Jonathan P. Anderson,John Chuah,Mark James Kelly,David Orth,Marcelo Wolff,Stefano Rusconi,Giuseppe Tambussi,Andrzej Horban,Francisco Antunes,Kamal Mansinho,J Vera,Hakima Himmich,Ploenchan Chetchotisakd,Pacharee Kantipong,Chloe Orkin,Simon Portsmouth,Alan Winston,Martin J. Wiselka,Gregory M. Anstead,Roberto C. Arduino,Matthew Bidwell Goetz,Karen Hennessey,Wafaa El-Sadr,Ann M. Labriola,Daniel E. Nixon,Maria C. Rodriguez-Barradas +113 more
TL;DR: IL-2 alone or with peri-cycle HAART increases CD4+ counts but was associated with a greater number of opportunistic events or deaths compared to no therapy, calling into question the immunoprotective significance of IL-2-inducedCD4+ cells.